Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

Authors :: Nébié I
Edwards NJ
Tiono AB
Ewer KJ
Sanou GS
Soulama I
Sanon S
Diarra A
Yaro JB
Kangoye D
Imoukhuede EB
Hill AV
Sirima SB
Source :: Clinical and vaccine immunology : CVI [Clin Vaccine Immunol] 2014 Jun; Vol. 21 (6), pp. 901-3. Date of Electronic Publication: 2014 Apr 16.
Publication Year :: 2014
Abstract: Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.<br /> (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)

Full Text Access

Tools